Literature DB >> 33398006

SARS-CoV-2 structural features may explain limited neutralizing-antibody responses.

Martin F Bachmann1,2,3, Mona O Mohsen4,5, Lisha Zha6, Monique Vogel6, Daniel E Speiser7.   

Abstract

Entities:  

Year:  2021        PMID： 33398006     DOI： 10.1038/s41541-020-00264-6

Source DB:  PubMed          Journal:  NPJ Vaccines        ISSN： 2059-0105            Impact factor:   7.344


× No keyword cloud information.
  1 in total

1.  Studies on the immunogenicity and tolerogenicity of T-independent antigens.

Authors:  R Z Dintzis; M H Middleton; H M Dintzis
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422
  1 in total
  24 in total

1.  A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice.

Authors:  Pascal Brandys; Xavier Montagutelli; Irena Merenkova; Güliz T Barut; Volker Thiel; Nicholas J Schork; Bettina Trüeb; Laurine Conquet; Aihua Deng; Aleksandar Antanasijevic; Hyun-Ku Lee; Martine Valière; Anoop Sindhu; Gita Singh; Jens Herold
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

2.  Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron.

Authors:  Anne-Cathrine S Vogt; Gilles Augusto; Byron Martina; Xinyue Chang; Gheyath Nasrallah; Daniel E Speiser; Monique Vogel; Martin F Bachmann; Mona O Mohsen
Journal:  Vaccines (Basel)       Date:  2022-05-09

3.  Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies.

Authors:  Anne-Cathrine S Vogt; Lukas Jörg; Byron Martina; Pascal S Krenger; Xinyue Chang; Andris Zeltins; Monique Vogel; Mona O Mohsen; Martin F Bachmann
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

4.  Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism.

Authors:  Martin F Bachmann; Mona O Mohsen; Daniel E Speiser
Journal:  NPJ Vaccines       Date:  2022-05-25       Impact factor: 9.399

5.  Peptide mediated colorimetric detection of SARS-CoV-2 using gold nanoparticles: a molecular dynamics simulation study.

Authors:  Nitu Verma; Yogesh Badhe; Rakesh Gupta; Auhin Kumar Maparu; Beena Rai
Journal:  J Mol Model       Date:  2022-06-24       Impact factor: 2.172

6.  BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced.

Authors:  Xinyue Chang; Gilles Sousa Augusto; Xuelan Liu; Thomas M Kündig; Monique Vogel; Mona O Mohsen; Martin F Bachmann
Journal:  Allergy       Date:  2021-05-20       Impact factor: 14.710

Review 7.  COVID-19: a new emerging respiratory disease from the neurological perspective.

Authors:  Amr El-Sayed; Lotfi Aleya; Mohamed Kamel
Journal:  Environ Sci Pollut Res Int       Date:  2021-02-15       Impact factor: 4.223

8.  AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate.

Authors:  Xuelan Liu; Xinyue Chang; Dominik Rothen; Mariliza Derveni; Pascal Krenger; Salony Roongta; Edward Wright; Monique Vogel; Kaspars Tars; Mona O Mohsen; Martin F Bachmann
Journal:  Vaccines (Basel)       Date:  2021-04-19

9.  Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles.

Authors:  Lisha Zha; Xinyue Chang; Hongxin Zhao; Mona O Mohsen; Liang Hong; Yuhang Zhou; Hongquan Chen; Xuelan Liu; Jie Zhang; Dong Li; Ke Wu; Byron Martina; Junfeng Wang; Monique Vogel; Martin F Bachmann
Journal:  Vaccines (Basel)       Date:  2021-04-16

10.  An Intramuscular DNA Vaccine for SARS-CoV-2 Decreases Viral Lung Load but Not Lung Pathology in Syrian Hamsters.

Authors:  Shanna S Leventhal; Chad Clancy; Jesse Erasmus; Heinz Feldmann; David W Hawman
Journal:  Microorganisms       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.